{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221595","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2026-05-13T20:05:19+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T22:12:24.357031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026","bullets":["Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.","Cash and equivalents $61.3M as of March 31, 2026; funded into 2029; includes $35M March private placement.","Phase 1 proof-of-mechanism study of EQ504 (AhR modulator) on track for mid-2026, data ~6 months later.","Appointed Snehal Naik, Ph.D., as Chief Development Officer; she brings >15 years immunology experience.","Evaluating further advancement of EQ302 (IL-15/IL-21 inhibitor) for GI indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221595","json":"https://secwatch.observer/filing/0001193125-26-221595.json","markdown":"https://secwatch.observer/filing/0001193125-26-221595.md","text":"https://secwatch.observer/filing/0001193125-26-221595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/0001193125-26-221595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:12:24.357031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}